ADHD Treatment Statistics in US 2026 | Key Facts

ADHD Treatment in the US 2026

ADHD treatment statistics in the United States reveal both unprecedented growth in diagnoses and persistent challenges in treatment access as the nation approaches 2026. As of 2022, approximately 7.1 million children aged 3-17 years had ever received an ADHD diagnosis, representing 11.4% (or approximately 1 in 9 children) of the pediatric population and marking an increase of 1 million children since 2016. Among adults, an estimated 15.5 million individuals (6.0%) had a current ADHD diagnosis by late 2023, nearly double the 2018 estimate of 8.7 million. The total number of Americans living with ADHD reached over 22 million in 2025, according to national estimates from CHADD analysts, representing one of the most commonly diagnosed neurodevelopmental conditions in the country. Among adults diagnosed with ADHD, approximately 55.9% received their diagnosis in adulthood at age 18 or older, and only about 44% had received diagnosis before turning 18, reflecting widespread underdiagnosis during childhood.

The treatment landscape faces critical access challenges despite growing recognition of the condition. Only 53.6% of children with current ADHD received medication in 2022 (down from 62% in 2016), while 44.4% received behavioral treatment, and nearly one-third (30.1%) of children with ADHD received no ADHD-specific treatment whatsoever, compared to 23% in 2016—representing a concerning worsening of the treatment gap affecting nearly 2 million children. Among adults taking stimulant medication, a staggering 71.5% reported difficulty filling their ADHD prescriptions during the previous year because medications were unavailable, reflecting the impact of widespread shortages that began in 2022 and continued through 2025, with ADHD medications listed on the FDA Drug Shortage Bulletin for the third consecutive year. National dispensing data shows that from 2012 to 2023, overall dispensing of stimulants in the United States increased by 60%, with particularly dramatic rises among adults. At health centers serving vulnerable populations in 2023, 41.7% of visits by adults with ADHD included amphetamine prescriptions, while 69.6% of these visits documented co-occurring mental health disorders including anxiety (51.2% of visits) and mood disorders (48.8%), underscoring the complex clinical presentations requiring comprehensive treatment approaches.

Interesting Facts and Latest Statistics on ADHD Treatment in the US 2025

Data sources: CDC National Survey of Children’s Health (2022), National Center for Health Statistics Rapid Surveys System (2023), CHADD national estimates (2025), CDC NCHS Data Brief #543 (December 2025)

The ADHD treatment statistics for children in the United States show a troubling paradox: while diagnoses have increased substantially with 7.1 million children having ever been diagnosed by 2022—an increase of 1 million since 2016—treatment access has actually worsened. Only 53.6% of children with current ADHD received medication in 2022, down from 62% in 2016, representing a significant decline in pharmacological treatment utilization. Behavioral treatment reached 44.4% of children (2.8 million), while 28.2% (1.8 million children) received the recommended combined approach of both medication and behavioral therapy. Most concerning is that 30.1% (nearly 2 million children) received no ADHD-specific treatment at all, up from 23% in 2016, indicating that despite increased awareness and diagnosis, the treatment gap has widened dramatically.

The adult ADHD population has experienced explosive growth, with 15.5 million adults having a current diagnosis by late 2023, nearly double the 8.7 million estimated in 2018. The total number of Americans living with ADHD reached over 22 million in 2025, according to CHADD analysts, making it one of the most commonly diagnosed neurodevelopmental conditions in the country. Among adults with ADHD, 55.9% were first diagnosed in adulthood at age 18 or older, while only about 44% received diagnosis before turning 18, highlighting massive childhood underdiagnosis. The stimulant dispensing trend shows a dramatic 60% increase from 2012 to 2023, with particularly sharp rises among adults. However, access remains severely compromised by medication shortages, with 71.5% of adults taking stimulants reporting difficulty filling prescriptions in the previous year because medications were unavailable—a crisis that has persisted for the third consecutive year according to the FDA Drug Shortage Bulletin (2025). At health centers in 2023, 41.7% of adult ADHD visits included amphetamine prescriptions, and 69.6% of visits documented co-occurring mental health disorders, demonstrating the complex treatment needs of this population.

Pediatric ADHD Diagnosis and Severity in the US 2022

Data sources: CDC National Survey of Children’s Health (NSCH) 2022, Journal of Clinical Child & Adolescent Psychology (2024), CDC Data and Statistics

The pediatric ADHD diagnosis landscape in the United States shows that approximately 1 in 9 children (11.4% or 7.1 million) aged 3-17 years have ever received an ADHD diagnosis as of 2022, with 6.5 million children (10.5%) having current ADHD. This represents a substantial increase of 1 million additional children diagnosed between 2016 and 2022, indicating a significant upward trend in both recognition and diagnosis of the condition. Gender disparities remain pronounced, with boys (15%) nearly twice as likely to be diagnosed compared to girls (8%), a gap that experts attribute partly to different symptom presentations, with girls more likely to exhibit inattentive symptoms that may be less disruptive and therefore less likely to prompt evaluation.

Racial and ethnic disparities reveal important patterns in diagnosis rates. Black children and White children are diagnosed at equal rates of 12%, both significantly higher than Asian children (4%), who show the lowest diagnosis prevalence. American Indian/Alaska Native children (10%) and Native Hawaiian/Pacific Islander children (6%) fall in between. Non-Hispanic children (12%) are diagnosed more often than Hispanic children (10%), suggesting possible differences in healthcare access, cultural factors affecting help-seeking, or diagnostic bias. Among children with current ADHD, 58.1% have moderate or severe ADHD (approximately 6 in 10 children), and a striking 77.9% have at least one co-occurring disorder. Children with both ADHD and another condition such as behavioral or conduct problems, learning disorders, anxiety, or depression more often had severe ADHD than children with ADHD alone, highlighting the complexity of clinical presentations and the need for comprehensive, multidisciplinary treatment approaches.

ADHD Treatment Patterns in Children in the US 2022

Data sources: CDC National Survey of Children’s Health (2022), State-level prevalence estimates (2016-2019), Treatment pattern analyses

The treatment patterns for children with ADHD reveal concerning trends in access to care and treatment utilization across the United States. Nearly 2 million children (30.1%) with ADHD received no treatment in 2022, representing a significant increase from 23% in 2016 and suggesting that despite increased awareness and diagnosis, treatment access has actually worsened over time. This gap represents a critical public health concern, as untreated ADHD can lead to academic failure, social problems, and increased risk of substance abuse and other mental health issues. Only 53.6% of children with current ADHD received medication in 2022, down substantially from 62% in 2016, indicating declining pharmacological treatment utilization despite growing diagnosis rates.

Behavioral treatment reached 44.4% of children with ADHD (2.8 million children) in 2022, representing an encouraging increase from 2.5 million in 2016. The combined treatment approach of both medication and behavioral therapy—considered the gold standard by the American Academy of Pediatrics for children aged 6 and older—was received by 28.2% of children (1.8 million), though this falls short of reaching the majority of affected children. Treatment rates vary dramatically by state, ranging from 58% to 92% of diagnosed children receiving some form of treatment, representing a 34 percentage point disparity in healthcare access across the United States. Northeastern states generally show higher treatment rates, while some Western and Southern states have lower rates despite higher diagnosis rates in the South. These patterns suggest that simply having access to diagnosis does not guarantee access to treatment, and that comprehensive ADHD care requires robust healthcare infrastructure, adequate provider training, and sufficient insurance coverage to ensure children receive evidence-based treatments.

Adult ADHD Diagnosis Growth in the US 2023-2025

Data sources: National Center for Health Statistics Rapid Surveys System (2023), CHADD estimates (2025), Johns Hopkins School of Public Health (2024), Health Psychology Research (Du 2025)

The adult ADHD diagnosis landscape has experienced explosive growth, with 15.5 million U.S. adults (6.0%) having a current ADHD diagnosis by late 2023, nearly double the 8.7 million estimated in 2018—representing an extraordinary increase in just five years. When combined with pediatric cases, the total number of Americans living with ADHD exceeded 22 million in 2025, according to national estimates from CHADD analysts, outpacing earlier predictions by nearly a decade and establishing ADHD as one of the most commonly diagnosed neurodevelopmental conditions in the country. The misconception that ADHD is primarily a childhood condition no longer holds true, as 13.1 million adults met ADHD diagnostic criteria in 2025, a sharp increase from roughly 8 million a decade earlier.

Among adults with ADHD, approximately 55.9% were first diagnosed in adulthood at age 18 or older, while only about 44% received diagnosis before turning 18, highlighting massive underdiagnosis during childhood, particularly among women and individuals with predominantly inattentive presentations. A recent small study found that an estimated 14% of adults remain undiagnosed with ADHD, with women more likely to be undiagnosed than men due to different symptom presentations—women are more likely to have inattentive symptoms than hyperactive symptoms, which may be less likely to lead to referral and diagnosis. The pandemic served as a major catalyst for adult diagnosis, with ADHD assessments increasing 37% between 2020 and 2024 according to Johns Hopkins School of Public Health. The shift toward remote work and learning exposed symptoms previously masked by rigid external structures, forcing millions to confront how their brains function without built-in accountability systems, leading to unprecedented levels of help-seeking and diagnosis among adults who had struggled silently for decades.

Adult ADHD Treatment Patterns in the US 2023

Data sources: National Center for Health Statistics Rapid Surveys System (2023), Adult ADHD treatment projections (2025), Telehealth utilization studies

Adult ADHD treatment patterns in the United States show that approximately half (50.3%) of adults with ADHD use medications, with 33.4% specifically taking stimulant medications as their treatment modality. Extrapolating from 2023 data to 2025 population estimates, approximately 8.11 million U.S. adults rely on stimulant medications, representing the first line of treatment for many adults. However, medication alone does not address all aspects of ADHD, as many adults continue struggling with organization, time management, and emotional regulation even with pharmacological treatment. The combined approach of both medication and behavioral treatment reaches 35.2% of adults with ADHD (approximately 5.68 million projected for 2025), representing the gold standard that addresses both symptom management and skill-building. An additional 13.3% (approximately 2.15 million adults) pursue counseling or behavioral treatment only, opting for non-medication approaches.

Most concerning is that 36.5% of adults with ADHD—more than one-third—receive no treatment whatsoever, leaving millions of adults to manage a neurobiological condition without professional support or evidence-based interventions. Telehealth has emerged as a critical access point, with approximately 50% of adults with ADHD having ever used telehealth services for ADHD care, including 30.5% for medication prescriptions and 30.8% for counseling or therapy. This digital expansion has proven particularly valuable for adults who face transportation barriers, scheduling conflicts with traditional office hours, or live in areas with limited specialist availability. The growing preference for a multifaceted approach to managing ADHD reflects a broader shift toward holistic care, with many adults combining medication with coaching, therapy, and lifestyle modifications to address the full spectrum of challenges associated with ADHD, though access barriers including cost, provider shortages, and medication availability continue to limit treatment uptake and continuity.

ADHD Medication Shortages and Access Challenges in the US 2023-2025

Data sources: National Center for Health Statistics Rapid Surveys System (2023), FDA Drug Shortage Bulletin (2025), IQVIA Stimulant Prescription Trends Report (2024), Family reports

ADHD medication shortages have created a public health crisis affecting millions of Americans, with 71.5% of adults taking stimulant medication reporting difficulty filling their ADHD prescriptions during the previous year because medications were unavailable. This staggering statistic reflects the impact of widespread shortages that began in 2022 and have persisted through 2025, with ADHD medications listed on the FDA Drug Shortage Bulletin for the third consecutive year. The shortages occur despite—or perhaps because of—a 60% increase in overall dispensing of stimulants from 2012 to 2023, as demand has outpaced manufacturing capacity and regulatory quotas set by the DEA for controlled substances.

The medication landscape shows that 90% of all dispensed ADHD medications were stimulants and only 10% were non-stimulant alternatives in 2022, creating dangerous over-reliance on a medication class subject to tight regulatory controls and manufacturing limitations. Clinicians report that shortages disproportionately affect low-income patients who rely on predictable generic formulations and lack the resources to try multiple pharmacies or pay out-of-pocket for brand-name alternatives. Some families reported needing to visit five or more pharmacies to secure a single refill, creating enormous burden and treatment disruptions that can lead to symptom exacerbation, academic or work problems, and increased risk of accidents or other adverse outcomes. The decline in children receiving medication from 62% in 2016 to 53.6% in 2022 likely reflects not only changing treatment preferences but also the practical challenges of maintaining consistent medication access in an environment of persistent shortages, forcing families and providers to explore alternative approaches or forego treatment entirely despite clear clinical need.

Health Center Visits for Adult ADHD in the US 2023

Data sources: CDC NCHS Data Brief #543 (December 2025), National Ambulatory Medical Care Survey Health Center Component (NAMCS HC) 2023

Health center visits for adult ADHD in the United States occurred at a rate of 52.6 visits per 10,000 adults in 2023, with a striking age gradient showing adults ages 18-24 had the highest rate (92.6 per 10,000) while those age 65 and older had the lowest (6.5 per 10,000), representing a nearly 14-fold difference between youngest and oldest adults. This pattern reflects both the recent surge in young adult diagnoses and the historical underdiagnosis of ADHD in older cohorts who aged out of the diagnostic window before adult ADHD was widely recognized. Health centers—local, community-based clinics serving populations who often encounter issues accessing healthcare—provide critical care access for vulnerable adults with ADHD.

Among health center visits by adults with ADHD, 41.7% included a documented amphetamine prescription (such as Adderall or Vyvanse), making stimulants the most common medication class, while overall approximately 55% of visits had at least one documented prescription for an ADHD medication including both stimulants and non-stimulants. Mental health comorbidities were extraordinarily common: 51.2% of visits documented a co-diagnosis of anxiety disorder, 48.8% had a mood disorder (including depression and bipolar disorder), 23.8% had substance use disorder, and overall 69.6% of visits included documentation of at least one of the selected mental health disorders. Physical health comorbidities were also prevalent, with 24.2% of visits documenting overweight or obesity, 13.1% hyperlipidemia, 12.8% hypertension, and 40.1% having at least one chronic condition not related to mental health. This high burden of co-occurring conditions underscores that adults with ADHD require comprehensive, integrated care addressing multiple medical and psychiatric needs simultaneously, rather than narrow ADHD-focused treatment alone.

Co-Occurring Conditions in Children with ADHD in the US 2022

Data sources: CDC National Survey of Children’s Health (2022), Journal of Clinical Child & Adolescent Psychology (2024), CDC comorbidity analyses

Co-occurring conditions affect nearly 4 in 5 children (77.9%) with ADHD, making comorbidity the norm rather than the exception. According to the 2022 national parent survey, approximately 78% of children with ADHD had at least one other co-occurring condition, fundamentally shaping the clinical presentation and treatment needs of affected children. Behavior or conduct problems represent the most common comorbidity, affecting almost half of children with ADHD, creating challenges in home, school, and community settings that extend beyond core ADHD symptoms of inattention, hyperactivity, and impulsivity. These oppositional and conduct issues often drive initial referrals for evaluation and contribute substantially to family stress and school disciplinary actions.

Anxiety disorders affect about 4 in 10 children (approximately 40%) with ADHD, creating emotional distress that compounds difficulties with focus and emotional regulation. Depression also occurs at elevated rates, though specific prevalence was not quantified in the national survey. Other important comorbidities include learning disorders, which create additional academic challenges beyond attention difficulties; autism spectrum disorder, which involves overlapping neurodevelopmental differences requiring specialized intervention approaches; and Tourette syndrome, involving tic disorders that occur at higher rates in children with ADHD. Critically, children with both ADHD and another co-occurring condition more often had severe ADHD than children with ADHD alone, suggesting that comorbidities either worsen ADHD symptom severity or that more severe ADHD increases vulnerability to developing additional conditions. This high comorbidity burden necessitates comprehensive assessment and treatment planning that addresses the full spectrum of a child’s needs rather than focusing narrowly on ADHD symptoms in isolation.

Geographic Variation in ADHD Diagnosis and Treatment in the US 2016-2019

Data sources: State-level estimates (2016-2019), Journal of Attention Disorders (2023), Geographic prevalence analyses

Geographic variation in ADHD diagnosis and treatment across the United States reveals substantial disparities in both recognition and access to care. National estimates among U.S. children aged 3-17 years who have ever been diagnosed with ADHD vary from 6% to 16% across states, representing a 10 percentage point spread that suggests dramatic differences in diagnostic practices, healthcare access, provider training, or underlying prevalence. Even more concerning, estimates for receiving any ADHD treatment among children with current ADHD vary from 58% to 92% across states, a 34 percentage point variation that represents profound inequality in healthcare access and quality across the nation.

Northeastern states generally show higher treatment rates, suggesting better healthcare infrastructure, more mental health providers, stronger insurance coverage, or cultural factors that support help-seeking for behavioral health conditions. Conversely, some Western and Southern states show lower treatment rates, with the Southern pattern being particularly paradoxical: higher diagnosis rates but lower treatment rates, indicating that children are being identified but not receiving needed services. These geographic patterns demonstrate that simply having access to diagnosis does not guarantee access to treatment, and that substantial barriers exist in many states preventing children with identified ADHD from receiving evidence-based interventions. The state-level variation likely reflects complex interactions between Medicaid expansion status, mental health parity law enforcement, provider workforce distribution, stigma levels, and socioeconomic factors that differentially affect families’ ability to navigate the healthcare system and access behavioral health services for their children with ADHD.

Disclaimer: This research report is compiled from publicly available sources. While reasonable efforts have been made to ensure accuracy, no representation or warranty, express or implied, is given as to the completeness or reliability of the information. We accept no liability for any errors, omissions, losses, or damages of any kind arising from the use of this report.

Email ID:

Please enable JavaScript in your browser to complete this form.

Email

Email *

SUBSCRIBE